N
NewAmsterdam Pharma
Developing transformative, clinically validated oral therapies for patients with metabolic diseases
About NewAmsterdam Pharma
NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company that focuses on the research and development of transformative oral therapies for major cardiometabolic diseases.
The company is investigating obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, as the preferred LDL-c-lowering therapy for high-risk cardiovascular disease (CVD) patients. The company's pipeline also includes a fixed-dose combination of obicetrapib and ezetimibe, which is in a Phase 2 clinical trial (ROSE2). NewAmsterdam is also conducting two Phase 3 pivotal trials, BROADWAY and BROOKLYN, to evaluate obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD). A third Phase 3 trial, PREVAIL, is designed as a cardiovascular outcomes trial. The company was founded in 2019 and is headquartered in Naarden, the Netherlands.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2019
- Headquarters
- Naarden, Netherlands
- Listing
- Public via SPAC 2022
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Forbion Capital Partners
Peter Thiel
Morningside- ABAscendant BioCapital
Series B and later8 investors entered at this stage
EQT Life Sciences
Frazier Healthcare Partners
Bain Capital Life Sciences
Panacea Venture
RA Capital Management
GMT Capital
Medicxi- FCFrazier Lifesciences Acquisition Corporation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about NewAmsterdam Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NewAmsterdam Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.